Milpharm Limited Pharmaceutical Import Profile — United Kingdom (DGFT 2022–2026)

Name: Milpharm Limited Pharmaceutical Import Records from India — 8 Products, $8.2M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Milpharm Limited — Pharmaceutical Importer Profile (2026) | 8 Products, $8.2M Trade | TransData Nexus

Milpharm Limited

Pharmaceutical Importer · United Kingdom · Cardiovascular Focus · $8.2M Total Trade · DGFT Verified

Milpharm Limited is a pharmaceutical importer based in United Kingdom with a total trade value of $8.2M across 8 products in 6 therapeutic categories. Based on 197 verified import shipments from Indian Customs (DGFT) records, Milpharm Limited is the #1 buyer in 1 product including Propranolol. Milpharm Limited sources from 10 verified Indian suppliers, with Aurobindo Pharma Limited accounting for 93.4% of imports.

Milpharm Limited — Import Portfolio & Supplier Network

Milpharm Limited import network — 8 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Milpharm Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Aurobindo Pharma Limited	$57.6M	3,481	93.4%
Eugia Pharma Specialities Limited	$1.9M	53	3.1%
Fourrts (india) Laboratories Private Limited

What Formulations Does Milpharm Limited Import?

Formulation	Value	Ships
Levetiracetam tablets	$655.3K	20
Finasteride tablets 5MG (finasteride 5mgfilm-coated tablets)	$613.2K	34
Gabapentin capsules 100MG(gabapentin	$581.2K	24
Finasteride tablets 5MG(finasteride 5MG	$544.5K	21
Mebeverine tablets 135MG(mebeverine	$523.1K	12
Sertraline hydrochloride tablets	$517.8K	12
Duloxetine 60 MG capsules(duloxetine	$515.2K	14
Clopidogrel tablets 75MG(clopidogrel	$464.3K	11
Levetiracetam tablets	$463.5K	19
Clopidogrel tablets 75MG (clopidogrel 75MG Film-Coated tablets)	$461.7K	16
Co-amoxiclav tablets	$450.0K	9
Losartan potassium tablets 100MG (losartan potassium 100MG Film-Coated tablets	$422.9K	16
Zopiclone tablets 7.5MG(zopiclone 7.5 MG	$419.8K	15
Sertraline hydrochloride tablets	$377.3K	9
Perindopril 4MG tablets(perindopril 4 MG	$372.7K	11

Milpharm Limited imports 1,738 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 8 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ramipril	Cardiovascular	$2.6M	52	2.9%	5
2	Gabapentin	CNS & Psychiatric	$2.5M	49	0.3%	17
3	Clarithromycin	Antibiotics	$997.3K	33	1.0%	15
4	Propranolol	Cardiovascular	$850.0K	17	1.5%	1
5	Isosorbide	Cardiovascular	$604.9K	15	1.3%	11
6	Sitagliptin	Diabetes & Endocrine	$550.0K	11	0.7%	19
7	Tamoxifen	Advanced Oncology	$101.0K	5	0.7%	15
8	Ribavirin	Antivirals	$75.9K	15	8.5%	3

Milpharm Limited imports 8 pharmaceutical products across 6 categories into United Kingdom totaling $8.2M. The company is the #1 buyer for 1 product: Propranolol.

Milpharm Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Milpharm Limited is a prominent pharmaceutical importer and distributor based in the United Kingdom, specializing in the supply of generic medicines. Established in 1997, the company has grown to become one of the top 10 generic pharmaceutical suppliers in the UK. In 2007, Milpharm was acquired by Aurobindo Pharma, a global leader in generic pharmaceuticals, which has a presence in over 150 countries and ranks among the world's top 10 generics companies by revenue.

Milpharm's headquarters are located at 1 Roundwood Avenue, Stockley Park, Uxbridge, Middlesex, UB11 1AF, United Kingdom. (find-and-update.company-information.service.gov.uk) The company plays a significant role in the UK's pharmaceutical distribution network by providing cost-effective generic medications that meet the needs of healthcare providers and patients. Its diverse product portfolio includes over 170 molecules covering various therapeutic areas such as neurology, oncology, cardiovascular, anti-retrovirals, gastroenterology, anti-diabetics, and antibiotics.

2Distribution Network

Milpharm Limited operates a robust distribution network within the United Kingdom, ensuring the efficient delivery of pharmaceutical products to a wide range of healthcare providers. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic partnerships and affiliations suggest a well-established infrastructure capable of supporting its extensive product portfolio. Milpharm's association with Aurobindo Pharma, which has manufacturing facilities approved by the UK's Medicines and Healthcare products Regulatory Agency (MHRA), further enhances its distribution capabilities.

3Industry Role

Milpharm Limited serves as a primary wholesaler and distributor of generic pharmaceutical products in the United Kingdom. By sourcing a diverse range of generic medicines, the company plays a crucial role in providing cost-effective alternatives to branded medications, thereby supporting the UK's healthcare system in managing costs while maintaining access to essential treatments. Milpharm's extensive product portfolio and established relationships with key customers in wholesale and NHS/hospital sectors underscore its significant position within the pharmaceutical supply chain.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Milpharm Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Milpharm Limited's sourcing strategy exhibits a high degree of concentration, with a significant portion of its imports originating from a single supplier, Aurobindo Pharma Limited. This supplier accounted for $57.6 million in imports, representing 93.4% of Milpharm's total imports from India. Such a concentrated sourcing approach can offer benefits like streamlined logistics and potentially better pricing due to bulk purchasing. However, it also introduces risks related to supply chain disruptions, quality control issues, and dependency on a single supplier's stability. The substantial volume of shipments from Aurobindo Pharma Limited indicates a stable and long-term relationship, which may mitigate some of these risks. Nonetheless, Milpharm's heavy reliance on one supplier suggests that any challenges faced by Aurobindo Pharma Limited could significantly impact Milpharm's operations.

2Supply Chain Resilience

Milpharm Limited's supply chain resilience is closely tied to its primary supplier, Aurobindo Pharma Limited. The company's heavy reliance on this single supplier for the majority of its imports from India indicates a potential vulnerability to supply chain disruptions. While the longstanding relationship with Aurobindo Pharma Limited may provide some stability, the lack of diversified sourcing strategies could pose challenges in the event of production issues, regulatory changes, or geopolitical factors affecting the supplier. To enhance supply chain resilience, Milpharm could consider diversifying its supplier base and establishing relationships with additional manufacturers to mitigate risks associated with over-reliance on a single source.

Importing Pharmaceuticals into United Kingdom — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United Kingdom

1Regulatory Authority & Framework

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) is the primary regulatory body overseeing the safety, quality, and efficacy of medicines and medical devices. The MHRA operates under the framework of the Human Medicines Regulations 2012, which transposes European Union directives into UK law. This legislation outlines the requirements for marketing authorizations, manufacturing, and distribution of medicinal products. For Indian pharmaceutical companies exporting to the UK, obtaining a UK marketing authorization is essential. This process involves submitting a comprehensive dossier to the MHRA, demonstrating that the product meets the necessary standards for safety, quality, and efficacy. The MHRA evaluates the application, and upon approval, grants a marketing authorization number, allowing the product to be legally marketed and sold in the UK.

2Import Licensing & GMP

Importing pharmaceutical products into the United Kingdom requires compliance with specific licensing and quality standards. Importers must hold a wholesale distribution authorization issued by the MHRA, which permits the storage and distribution of medicinal products. Additionally, the imported products must be accompanied by a Good Manufacturing Practice (GMP) certificate. The MHRA recognizes GMP certificates from countries with established regulatory frameworks, such as the European Union (EU), World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). For Indian exporters, ensuring that their manufacturing facilities are certified by these recognized bodies is crucial for facilitating the importation of their products into the UK market.

Milpharm Limited — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Milpharm Limited's product strategy focuses on providing a diverse range of generic pharmaceutical products across various therapeutic areas, including neurology, oncology, cardiovascular, anti-retrovirals, gastroenterology, anti-diabetics, and antibiotics. This broad portfolio allows Milpharm to meet the varied needs of the UK healthcare system and its patients. The company's emphasis on generic medicines aligns with the UK's healthcare policy to reduce costs while maintaining access to essential treatments. By offering cost-effective alternatives to branded medications, Milpharm supports the sustainability of the healthcare system and ensures that patients have access to necessary therapies.

2Sourcing Profile

Milpharm Limited's sourcing strategy is heavily reliant on its parent company, Aurobindo Pharma Limited, which supplies the majority of Milpharm's imported pharmaceutical products. This centralized sourcing approach allows Milpharm to leverage Aurobindo's global manufacturing capabilities and established quality standards. However, the concentration of sourcing from a single supplier may expose Milpharm to risks associated with supply chain disruptions or changes in the supplier's operational status. To mitigate these risks, Milpharm could consider diversifying its supplier base by engaging with additional manufacturers, particularly those with recognized GMP certifications and a track record of compliance with UK regulatory standards.

Seller's Guide — How to Become a Supplier to Milpharm Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Milpharm Limited's supply chain, particularly if they can offer competitive pricing, consistent quality, and reliable delivery schedules. Mil

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Milpharm Limited

What products does Milpharm Limited import from India?

Milpharm Limited imports 8 pharmaceutical products across 6 categories. Top imports: Ramipril ($2.6M), Gabapentin ($2.5M), Clarithromycin ($997.3K), Propranolol ($850.0K), Isosorbide ($604.9K).

Who supplies pharmaceuticals to Milpharm Limited from India?

Milpharm Limited sources from 10 verified Indian suppliers. The primary supplier is Aurobindo Pharma Limited (93.4% of imports, $57.6M).

What is Milpharm Limited's total pharmaceutical import value?

Milpharm Limited's total pharmaceutical import value from India is $8.2M, based on 197 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Milpharm Limited focus on?

Milpharm Limited imports across 6 categories. The largest: Cardiovascular (49.3%), CNS & Psychiatric (29.8%), Antibiotics (12.1%).

Get Full Milpharm Limited Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.